Lynparza (olaparib) / Merck (MSD), AstraZeneca 
Welcome,         Profile    Billing    Logout  

209 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lynparza (olaparib) / Merck (MSD), AstraZeneca
NCT05457257: Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

Active, not recruiting
4
43
RoW
olaparib, Lynparza, enzalutamide, XTANDI, abiraterone acetate, ZYTIGA, Prednisone
AstraZeneca, Merck Sharp & Dohme LLC, Foundation Medicine, Inc., Myriad Genetics, Inc.
Metastatic Castration-resistant Prostate Cancer
06/24
09/25
IOLANTHE, NCT06121401: First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients

Recruiting
4
190
Europe
Olaparib, Lynparza, Bevacizumab
Mario Negri Institute for Pharmacological Research, AstraZeneca
Carcinoma, Ovarian Epithelial
03/27
09/27
NCT01924533: Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.

Checkmark GOLD trial for 2nd-line gastric cancer
May 2016 - May 2016: GOLD trial for 2nd-line gastric cancer
Checkmark Completion of enrollment in P3 GOLD trial for 2nd-line gastric cancer
Aug 2015 - Aug 2015: Completion of enrollment in P3 GOLD trial for 2nd-line gastric cancer
Completed
3
525
Japan, RoW
Olaparib, Paclitaxel, Placebo
AstraZeneca
Gastric Cancer
04/16
03/23
SOLO-2, NCT01874353 / 2013-001211-75: Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Checkmark From SOLO2 trial in relapsed BRCA mutated ovarian cancer at ASCO 2020
Jun 2020 - Jun 2020: From SOLO2 trial in relapsed BRCA mutated ovarian cancer at ASCO 2020
Checkmark From SOLO 2 trial in first-line ovarian cancer at ASCO 2020
May 2020 - May 2020: From SOLO 2 trial in first-line ovarian cancer at ASCO 2020
Checkmark QoL data in germline BRCA1/2-mutated ovarian cancer
More
Active, not recruiting
3
327
Europe, Canada, Japan, US, RoW
Olaparib 300mg tablets, Placebo to match olaparib 300mg
AstraZeneca, European Network of Gynaecological Oncological Trial Groups (ENGOT), Myriad Genetic Laboratories, Inc., Merck Sharp & Dohme LLC
Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
09/16
12/24
OlympiAD, NCT02000622 / 2013-005137-20: Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

Checkmark In gBRCA-mutated HER2-negative metastatic breast cancer
Apr 2018 - Apr 2018: In gBRCA-mutated HER2-negative metastatic breast cancer
Checkmark OlympiAD trial for BRCAm metastatic breast cancer at ASCO 2017
Jun 2017 - Jun 2017: OlympiAD trial for BRCAm metastatic breast cancer at ASCO 2017
Active, not recruiting
3
302
Europe, Japan, US, RoW
Olaparib, Physician's choice chemotherapy
AstraZeneca, Myriad Genetic Laboratories, Inc., Merck Sharp & Dohme LLC
Breast Cancer Metastatic, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation
12/16
12/24
2017-000161-75: ICON9 is a research study investigating patients with recurrent ovarian, fallopian tube or primary peritoneal cancer, who have had their tumour shrunk by chemotherapy. The study will address whether such patients may benefit from maintenance treatment with two new anti-cancer, orally-administrated drugs called olaparib and cediranib.

Not yet recruiting
3
618
Europe
Olaparib, Cediranib, AZD2171 Maleate, Film-coated tablet, Lynparza
University College London, Cancer Research UK, AstraZeneca UK Limited
High grade serous or endometrioid ovarian, fallopian and peritoneal cancer, Ovarian, fallopian and peritoneal cancer, Diseases [C] - Cancer [C04]
 
 
SOLO-1, NCT01844986 / 2013-001551-13: Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

Checkmark Seven-year follow-up from P3 SOLO-1 trial for ovarian cancer at ESMO 2022
Sep 2022 - Sep 2022: Seven-year follow-up from P3 SOLO-1 trial for ovarian cancer at ESMO 2022
Checkmark Presentation of data from SOLO-1 trial in 1L ovarian cancer at SGO 2021
May 2021 - May 2021: Presentation of data from SOLO-1 trial in 1L ovarian cancer at SGO 2021
Checkmark Presentation of data from SOLO-1 trial in 1L ovarian cancer at ESMO 2020
More
Active, not recruiting
3
450
Europe, Canada, Japan, US, RoW
Olaparib 300mg tablets
AstraZeneca, GOG Foundation, Myriad Genetic Laboratories, Inc., Merck Sharp & Dohme LLC
Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation, Complete Response, Partial Response, First Line Platinum Chemotherapy
05/18
08/28
2017-002851-27: GENETIC SEQUENCING FOR THE TREATMENT OF ADVANCED SOFT-TISSUE SARCOMAS SEQUENCAGE GENETIQUE POUR LE TRAITEMENT DES SARCOMES DES TISSUS MOUS

Not yet recruiting
3
960
Europe
CAPMATINIB, OLAPARIB, DURVALUMAB, GLASDEGIB, TAS-120, INC280, AZD2281, MEDI4736, PF-04449913, TAS-120, Capsule, hard, Film-coated tablet, Concentrate for solution for infusion, Tablet, TASIGNA, ZYKADIA, TYVERB, MEKINIST, TAFINLAR, LYNPARZA, IBRANCE
INSERM, Institut National du Cancer (INCa)
Adult patients with locally advanced/unresectable and/or metastatic soft-tissue sarcoma, Adult patients with advanced soft-tissue sarcoma, Diseases [C] - Cancer [C04]
 
 
POLO, NCT02184195 / 2014-001589-85: Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

Checkmark From POLO trial for gBRCAm and metastatic pancreatic cancer at ASCO 2019 [screenshot]
Jun 2019 - Jun 2019: From POLO trial for gBRCAm and metastatic pancreatic cancer at ASCO 2019 [screenshot]
Checkmark From POLO trial in 1L gBRCA+ pancreatic cancer
Feb 2019 - Feb 2019: From POLO trial in 1L gBRCA+ pancreatic cancer
Completed
3
154
Europe, Canada, US, RoW
Olaparib, Placebo
AstraZeneca, Myriad Genetic Laboratories, Inc., Merck Sharp & Dohme LLC
Germline BRCA1/2 Mutations and, Metastatic Adenocarcinoma of the Pancreas
01/19
01/23
PROfound, NCT02987543 / 2016-000300-28: Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer ( Study)

Checkmark Quality of life data from PROfound trial in mCRPC
Feb 2022 - Feb 2022: Quality of life data from PROfound trial in mCRPC
Checkmark Follow-up data from PROfound trial for metastatic castration resistant prostate cancer at ESMO 2020
Sep 2020 - Sep 2020: Follow-up data from PROfound trial for metastatic castration resistant prostate cancer at ESMO 2020
Checkmark Data from PROfound trial for mCRPC at ESMO 2020
More
Completed
3
387
Europe, Canada, Japan, US, RoW
olaparib, Lynparza, enzalutamide, XTANDI, abiraterone acetate, ZYTIGA
AstraZeneca, Merck Sharp & Dohme LLC, Foundation Medicine, Inc., Myriad Genetics, Inc.
Metastatic Castration-resistant Prostate Cancer
06/19
02/23
2018-004720-11: Phase 3 Study of Pembrolizumab with Maintenance Olaparib or Maintenance Pemetrexed in 1L Metastatic Nonsquamous NSCLC

Ongoing
3
792
Europe, RoW
KEYTRUDA® (pembrolizumab, MK-3475), Pembrolizumab, Olaparib, ALIMTA, Pemetrexed, MK-3475, MK-7339, Solution for infusion, Film-coated tablet, Powder for concentrate for solution for infusion, KEYTRUDA® (pembrolizumab, MK-3475), ALIMTA
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,
Stage IV lung cancer condition, Stage IV lung cancer condition, Diseases [C] - Cancer [C04]
 
 
NRG-GY004, NCT02446600: Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Checkmark From GY004 trial in combination with cediranib for recurrent platinum sensitive ovarian cancer
Mar 2020 - Mar 2020: From GY004 trial in combination with cediranib for recurrent platinum sensitive ovarian cancer
Active, not recruiting
3
579
Canada, Japan, US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cediranib Maleate, AZD2171, AZD2171 Maleate, Recentin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Gemcitabine Hydrochloride, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pegylated Liposomal Doxorubicin Hydrochloride, ATI-0918, Caelyx, Dox-SL, Doxil, Doxilen, Doxorubicin HCl Liposomal, Doxorubicin HCl Liposome, Doxorubicin Hydrochloride Liposome, Duomeisu, Evacet, LipoDox, Lipodox 50, Liposomal Adriamycin, Liposomal Doxorubicin Hydrochloride, Liposomal-Encapsulated Doxorubicin, Pegylated Doxorubicin HCl Liposome, Pegylated Liposomal Doxorubicin, S-Liposomal Doxorubicin, Stealth Liposomal Doxorubicin, TLC D-99, Pharmacological Study, Quality-of-Life Assessment, Quality of Life Assessment
National Cancer Institute (NCI), AstraZeneca, NRG Oncology
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Tumor, Ovarian Seromucinous Carcinoma, Ovarian Serous Tumor, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal Carcinoma
02/20
08/24
2019-000698-22: Olaparib +/- bevacizumab in CRC with SD/PR/CR from FOLFOX with bevacizumab.

Ongoing
3
525
Europe
Olaparib, MK-7339, Film-coated tablet, Concentrate for solution for infusion, Solution for injection/infusion, Avastin (Bevacizumab), 5-Fluorouracil-Ebewe (5-FU)
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc
The treatment of participants with unresectable or metastatic CRC that has not progressed following an induction course of FOLFOX + bevacizumab, Advanced Metastatic Colorectal Cancer (Has not progressed after completing at least 6 prior induction cycles of FOLFOX + Bevacizumab and can no longer tolerate any components of FOLFOX), Diseases [C] - Cancer [C04]
 
 
OlympiA, NCT02032823 / 2013-003839-30: Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer

Hourglass Apr 2023 - Jun 2023 : Acceptance of regulatory submission fin China for breast cancer (based on OlympiA trial)
Checkmark From OlympiA trial in germline BRCA-mutated, HER2-negative high-risk early breast cancer
Mar 2022 - Mar 2022: From OlympiA trial in germline BRCA-mutated, HER2-negative high-risk early breast cancer
Checkmark From OlympiA trial for breast cancer at ASCO 2021
Jun 2021 - Jun 2021: From OlympiA trial for breast cancer at ASCO 2021
More
Active, not recruiting
3
1836
Europe, Canada, Japan, US, RoW
Olaparib, Lynparza, Placebo
AstraZeneca, Breast International Group, Frontier Science & Technology Research Foundation, Inc., NRG Oncology, Myriad Genetic Laboratories, Inc., Br.E.A.S.T. -Data Center & Operational Office Institut Jules Bordet, Merck Sharp & Dohme LLC
Breast Cancer
03/20
05/29
2021-000245-41: Olaparib beyond progression compared to platinum chemotherapy after secondary cytoreductive surgery in recurrent ovarian cancer patients. The phase III randomized, open label MITO 35b study: a project of the MITO-MANGO groups. Trattamento con Olaparib oltre la progressione confrontato con chemioterapia a base di platino dopo citoriduzione secondaria in pazienti con recidiva da carcinoma ovarico. MITO 35b, studio di fase 3 randomizzato: un progetto dei Gruppi MITO-MANGO.

Ongoing
3
200
Europe
CARBOPLATINO, LYNPARZA, Cisplatino, Gemcitabina, Paclitaxel, Doxorubicina Liposomiale Pegilata, [CARBOPLATINO], [LYNPARZA], [Cisplatino], [Gemcitabina], [Paclitaxel], [Doxorubicina Liposomiale Pegilata], Concentrate for solution for infusion, Film-coated tablet, LYNPARZA - 100 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (ALU/ALU) - 56 COMPRESSE, LYNPARZA - 150 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (ALU/ALU) - 56 COMPRESSE
ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE, AstraZeneca S.p.A.
Recurrent ovarian cancer patients Pazienti con recidiva da carcinoma ovarico, Recurrent ovarian cancer patients Pazienti con recidiva da carcinoma ovarico, Diseases [C] - Cancer [C04]
 
 
PROPEL, NCT03732820 / 2018-002011-10: Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

Jan 2022 - Dec 2023: Acceptance of regulatory submission in China in combination with abiraterone for prostate cancer (based on PROpel trial)
Checkmark Data from PROPEL trial in combination with abiraterone for mCRPC at ESMO 2022
Sep 2022 - Sep 2022: Data from PROPEL trial in combination with abiraterone for mCRPC at ESMO 2022
Checkmark Data from PROPEL trial in combination with abiraterone for mCRPC
Jun 2022 - Jun 2022: Data from PROPEL trial in combination with abiraterone for mCRPC
More
Active, not recruiting
3
895
Europe, Canada, Japan, US, RoW
olaparib, Lynparza, abiraterone acetate, Zytiga
AstraZeneca, Merck Sharp & Dohme LLC
Metastatic Castration-resistant Prostate Cancer
07/21
04/26
KEYLYNK-010, NCT03834519 / 2018-004118-16: Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/)

Not Appicable Jan 2022 - Dec 2022 : From KEYLYNK-010 trial in combination with Lynparza for metastatic CRPC
Checkmark Presentation of data from KEYLYNK-010 trial for mCRPC at ESMO 2022
Sep 2022 - Sep 2022: Presentation of data from KEYLYNK-010 trial for mCRPC at ESMO 2022
Completed
3
793
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Olaparib, MK-7339, AZD-2281, LYNPARZA®, Abiraterone acetate, ZYTIGA®, CB-7630, JNJ-212082, Prednisone, Enzalutamide, XTANDI®, MDV-3100, ASP-9785, Prednisolone
Merck Sharp & Dohme LLC
Prostatic Neoplasms
03/22
01/24
LYNK-003, NCT04456699 / 2019-000698-22: Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/)

Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission for CRC (based on LYNK-003 trial)
Calendar Jan 2024 - Dec 2024: Data from LYNK-003 trial for 1L colorectal cancer
Checkmark Termination of P3 LYNK-003 trial in unresectable or metastatic CRC
Jul 2022 - Jul 2022: Termination of P3 LYNK-003 trial in unresectable or metastatic CRC
Completed
3
335
Europe, Canada, Japan, US, RoW
Olaparib, LYNPARZA^TM, 5-FU, Fluorouracil, Adrucil, Efudex, Bevacizumab, MVASI^TM, Avastin, Capecitabine, XELODA^®, Leucovorin/ levoleucovorin, Folinic Acid, Fusilev^®, Khapzory^TM
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc
Metastatic Colorectal Cancer
03/23
11/23
DUO-O, NCT03737643 / 2017-004632-11: Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in combination with Lynparza for 1L ovarian cancer (based on DUO-O trial)
Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in US in combination with Imfinzi for 1L ovarian cancer (based on DUO-O trial)
Jan 2023 - Jun 2023: Data from DuO-O trial in combination with Imfinzi for advanced ovarian cancer
Active, not recruiting
3
1407
Europe, Canada, Japan, US, RoW
Bevacizumab, Durvalumab, Olaparib, Placebo olaparib, Durvalumab placebo, Carboplatin+Paclitaxel
AstraZeneca, European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation, Inc. (GOG Foundation), Myriad Genetic Laboratories, Inc.
Advanced Ovarian Cancer
09/23
05/28
DUO-E, NCT04269200 / 2019-004112-60: Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in combination with Lynparza for endometrial cancer (based on DuO-E trial)
Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in combination with Imfinzi for endometrial cancer (based on DuO-E trial)
Jan 2022 - Dec 2023: From STRONG trial in combinaton with tremelimumab advanced solid malignancies
Jul 2023 - Dec 2023: Data from DUO-E trial in combination with Imfinzi for 1L endometrial cancer
Hourglass Jan 2022 - Dec 2023 : Acceptance of regulatory submission in Japan in combination with Lynparza (based on DuO-E trial) for 1L endometrial cancer
More
Active, not recruiting
3
805
Europe, Canada, Japan, US, RoW
olaparib, durvalumab, durvalumab placebo, olaparib placebo, Carboplatin, Paclitaxel
AstraZeneca, The Gynecologic Oncology Group (GOG) Foundation Inc, The European Network for Gynaecological Oncological Trial groups (ENGOT)
Endometrial Neoplasms
07/24
08/27
L-MOCA, NCT03534453: Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Active, not recruiting
3
229
RoW
Olaparib 300mg tablets
AstraZeneca
Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy, Platinum Sensitive
12/24
12/24
ENGOT-ov43, NCT03740165 / 2018-001973-25: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001//GOG-3036)

Hourglass Jan 2023 - Dec 2023 : From KEYLYNK-001 trial in combination with Keytruda for 1L non epithelial BRCA ovarian cancer
Active, not recruiting
3
1367
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Placebo for pembrolizumab, normal saline or dextrose, Carboplatin, PARAPLATIN®, Paclitaxel, TAXOL®, Olaparib, MK-7339, LYNPARZA®, Placebo for olaparib, Bevacizumab, AVASTIN®, Docetaxel
Merck Sharp & Dohme LLC, European Network of Gynaecological Oncological Trial Groups (ENGOT), Gynecologic Oncology Group
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
08/24
05/26
EPIK-O, NCT04729387 / 2019-004682-40: Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

Active, not recruiting
3
358
Europe, Canada, US, RoW
Alpelisib, BYL719, Olaparib, Paclitaxel, Pegylated liposomal doxorubicin (PLD)
Novartis Pharmaceuticals
Ovarian Cancer
04/23
01/26
PROpel Study, NCT05171816: Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)

Active, not recruiting
3
108
RoW
olaparib, Lynparza, abiraterone acetate, Zytiga
AstraZeneca, Merck Sharp & Dohme LLC
Metastatic Castration-resistant Prostate Cancer
01/24
04/26
KEYLYNK-008, NCT03976362 / 2018-004721-88: A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/)

Apr 2024 - Jun 2024: From KEYLYNK-008 trial +/- Lynparza for 1L metastatic NSCLC
Active, not recruiting
3
591
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, Carboplatin, PARAPLATIN®, Paclitaxel, TAXOL®, ONXAL™, Nab-paclitaxel, ABRAXANE®, Olaparib, LYNPARZA®, Placebo
Merck Sharp & Dohme LLC
Carcinoma, Squamous Cell, Non-small-cell Lung
09/23
03/25
MONO-OLA1, NCT04884360 / 2020-005960-68: D9319C00001- 1L OC Mono Global RCT

Calendar Jan 2024 - Dec 2024: Data from MONO-OLA1 trial for BRCAwt advanced ovarian cancer
Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission for 1L BRCAwt ovarian cancer (based on MONO-OLA1 trial)
Recruiting
3
420
Europe, RoW
Olaparib, Matching placebo
AstraZeneca
Ovarian Cancer
07/24
07/25
KEYLYNK-006, NCT03976323 / 2018-004720-11: Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Non-squamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, )

Calendar Jul 2024 - Sep 2024: From KEYLYNK-006 trial +/- Lynparza for 1L metastatic non squamous NSCLC
Active, not recruiting
3
672
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA®, Pemetrexed, ALIMTA®, Carboplatin, PARAPLATIN®, Cisplatin, PLATINOL®, PLATINOL®-AQ, Olaparib, LYNPARZA®
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,
Carcinoma, Non-squamous Non-small-cell Lung
02/24
01/25
ROSY-O, NCT04421963 / 2019-003777-26: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib

Enrolling by invitation
3
292
Europe, Canada, US, RoW
Olaparib
AstraZeneca
Ovarian Cancer, Breast Cancer
12/24
12/24
KEYLYNK-012, NCT04380636 / 2019-003237-41: Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/)

Calendar Jan 2026 - Dec 2026: Data from KEYLINK-012 trial in combination with Lynparza for stage III NSCLC
Active, not recruiting
3
870
Europe, Canada, Japan, US, RoW
Pembrolizumab, KEYTRUDA®, MK-3475, Olaparib, LYNPARZA®, MK-7339, AZD2281, KU-0059436, Placebo for olaparib, Etoposide, VEPESID®, Carboplatin, PARAPLATIN®, Cisplatin, PLATINOL®, Paclitaxel, TAXOL®, Pemetrexed, ALIMTA®, Thoracic Radiotherapy, Durvalumab, IMFINZI®
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
07/26
02/27
KEYLYNK-013, NCT04624204 / 2019-003616-31: Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/)

Recruiting
3
672
Europe, Canada, Japan, US, RoW
Pembrolizumab 200 mg, MK-3475, KEYTRUDA®, Pembrolizumab 400 mg, Pembrolizumab placebo (saline), Olaparib 300 mg BID, MK-7339, LYNPARZA®, Olaparib matching placebo, Etoposide 100 mg/m^2, Platinum, investigator's choice, Standard Thoracic Radiotherapy, Prophylactic Cranial Irradiation (PCI)
Merck Sharp & Dohme LLC
Small Cell Lung Cancer
10/27
10/27
TROPION-Breast04, NCT06112379: A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

Recruiting
3
1728
Europe, Canada, Japan, US, RoW
Dato-DXd, Datopotamab deruxtecan (Dato-DXd, DS-1062a), Durvalumab, MEDI4736, Pembrolizumab, KEYTRUDA®, Doxorubicin, Epirubicin, Cyclophosphamide, Paclitaxel, Carboplatin, Capecitabine, XELODA®, Capecitabine Cell Pharm, Capecitabine EG, Capecitabine Accord, Olaparib, LYNPARZA®
AstraZeneca, Daiichi Sankyo
Breast Cancer
03/28
08/30
PARTNER, NCT03150576: Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer

Recruiting
2/3
780
Europe
Olaparib, Lynparza, Paclitaxel and Carboplatin, Taxol and Paraplatin
Cambridge University Hospitals NHS Foundation Trust, AstraZeneca, Cancer Research UK
Breast Cancer
06/24
06/34
RAINBO, NCT05255653: Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features

Recruiting
2/3
1615
Europe, Canada
Olaparib, Lynparza, Pelvic external beam radiotherapy, EBRT, Chemotherapy, Cisplatin, Carboplatin, Paclitaxel, Durvalumab, Imfinzi, Medroxyprogesterone Acetate, Progestogen, Megestrol Acetate, Vaginal brachytherapy, Observation
Leiden University Medical Center, Institute Gustave Roussy (sponsor p53abn-RED trial), Leiden University Medical center (sponsor MMRd-GREEN trial), University College London (sponsor NSMP-ORANGE trial), Canadian Clinical Trials Group (sponsor POLEmut-BLUE trial), Dutch Gynaecological Oncology Group, Comprehensive Cancer Centre The Netherlands, Cancer Research UK & UCL Cancer Trials Centre, Dutch Cancer Society, AstraZeneca, National Cancer Institute, France, Canadian Institutes of Health Research (CIHR)
Endometrial Cancer
01/30
01/31
2020-004859-32: Olaparib and durvalumab (MEDI4736) in patients with metastatic pancreatic cancer and DNA Damage Repair genes alterations Olaparib y durvalumab (MEDI4736) en pacientes con cáncer de páncreas metastásico y alteraciones en los genes de reparación de daño en el ADN

Ongoing
2
40
Europe
Concentrate for solution for infusion, Film-coated tablet, IMFINZI, Lynparza
Grupo de Tratamiento de los Tumores Digestivos (TTD), Astra Zeneca
Metastatic pancreatic cancer and DNA Damage Repair genes alterations Cáncer de páncreas metastásico y alteraciones en los genes de reparación de daño en el ADN, Metastatic pancreatic cancer Cáncer de páncreas metastásico, Diseases [C] - Cancer [C04]
 
 
NCT00753545 / 2008-003439-18: Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

Checkmark In ovarian cancer at ASCO 2016
Jun 2016 - Jun 2016: In ovarian cancer at ASCO 2016
Checkmark In patients with platinum sensitive ovarian cancer
Jun 2016 - Jun 2016: In patients with platinum sensitive ovarian cancer
Checkmark ASCO 2016
More
Completed
2
265
Europe, Canada, US, RoW
AZD2281, Olaparib, Lynparza, matching placebo
AstraZeneca
Ovarian Cancer
06/10
10/23
NCT01081951 / 2009-015970-36: Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

Checkmark ECCO-ESMO-ESTRO 2013
Sep 2013 - Sep 2013: ECCO-ESMO-ESTRO 2013
Active, not recruiting
2
162
Europe, Canada, Japan, US, RoW
olaparib, Lynparza, paclitaxel, Taxol, carboplatin, Drug: carboplatin
AstraZeneca
Ovarian Cancer
10/11
12/24
NCT01063517: Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients

Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Completed
2
124
RoW
olaparib, paclitaxel, Taxol, Placebo
AstraZeneca
Gastric Cancer
05/12
06/23
NCT01078662 / 2010-022278-15: Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

Checkmark ovarian cancer
Jan 2016 - Jan 2016: ovarian cancer
Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Checkmark
More
Active, not recruiting
2
298
Europe, RoW
olaparib, Lynparza
AstraZeneca
Ovarian, Breast, Prostate, Pancreatic, Advanced Tumours
07/12
12/24
2013-001652-36: Evaluation of the efficacy of high throughput genome analysis as a therapeutic decision tool for patients with metastatic breast cancer

Not yet recruiting
2
240
Europe
AZD2014, AZD4547, AZD5363, AZD8931, Selumetinib, Vandetanib, Bicalutamide, Olaparib, AZD6244, ZD6474, AZD 2281, Tablet, Capsule, , CAPRELSA, CASODEX
UNICANCER, Astra Zeneca Laboratories
Patients with metastatic breast cancer in 1st or 2nd line of chemotherapy, breast cancer, Diseases [C] - Cancer [C04]
 
 
2016-003964-38: Clinical study, involving Italian clinical sites, comparing the activity of Paclitaxel (weekly administration) to the activity of Cediranib-Olaparib with continuous administration or to Cediranib-Olaparib with intermittent administration, in patients with advanced ovarian cancer, resistant to previous platinum treatment. Studio Barocco: Studio clinico che coinvolge più centri clinici italiani volto a comparare l’attività di paclitaxel somministrato settimanalmente con quella di cediranib e olaparib somministrati in modo continuo o cediranib e olaparib somministrati in modo intermittente, nelle pazienti con tumore dell’ovaio avanzato, resistente a trattamenti a base di platino.

Not yet recruiting
2
100
Europe
Cediranib, Olaparib, Paclitaxel, [Not Applicable], [Not applicable], [n.a.], Tablet, Solution for infusion, PACLITAXEL MYLAN GENERICS - 6 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO DI VETRO DA 16.7 ML
IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI, AstraZeneca S.p.A.
resistant high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer. carcinoma epiteliale ovarico ad alto grado, carcinoma delle tube di falloppio e carcinoma peritoneale primitivo, resistente al platino., ovarian cancer, resistant to previous platinum treatment. tumore dell’ovaio avanzato, resistente al trattamento a base di platino., Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]
 
 
NCT01972217 / 2013-003520-37: Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.

Checkmark For P2 trial in mCRPC
Jun 2020 - Jun 2020: For P2 trial in mCRPC
Checkmark Study 08 data in combination with abiraterone in mCRPC at ASCO 2018
Jun 2018 - Jun 2018: Study 08 data in combination with abiraterone in mCRPC at ASCO 2018
Checkmark Completion of enrollment in P2 trial for metastatic castration resistant prostate cancer
More
Completed
2
158
Europe, Canada, US, RoW
Olaparib, PARP inhibition, Placebo, Placebo to PARP inhibition, Abiraterone, Prednisone or prednisolone
AstraZeneca, Merck Sharp & Dohme LLC
Metastatic Castration-resistant Prostate Cancer
09/17
08/23
2016-004617-28: Does cediranib together with paclitaxel chemotherapy, or cediranib and olaparib, treat advanced endometrial cancer better than paclitaxel chemotherapy?

Not yet recruiting
2
129
Europe
Olaparib (Lynparza), Cediranib, Paclitaxel, AZD2281, AZD2171, Film-coated tablet, Concentrate for solution for infusion, Olaparib (Lynparza)
The University of Manchester, AstraZeneca Ltd
Advanced or recurrent endometrial carcinoma or carcinosarcoma, Endometrial cancer, Diseases [C] - Cancer [C04]
 
 
2016-004618-93: Is it safe to add Cediranib to weekly paclitaxel chemotherapy in women with ovarian cancer who are at risk of developing malignant bowel obstruction?

Ongoing
2
30
Europe
Olaparib (Lynparza), Cediranib, Paclitaxel, AZD2281, AZD2171, Film-coated tablet, Concentrate for solution for infusion, Olaparib (Lynparza), Paclitaxel
University of Manchester, AstraZeneca
Platinum-Resistant Ovarian Cancer, Ovarian Cancer that has not responded to treatment with platinum containing chemotherapy., Diseases [C] - Cancer [C04]
 
 
2016-004215-13: Randomised Phase II Trial of Cediranib and Olaparib Maintenance in Advanced/Recurrent Cervical Cancer

Not yet recruiting
2
108
Europe
Cediranib, Olaparib, AZD2171, AZD2281, Film-coated tablet
The Clatterbridge Cancer Centre NHS Foundation, AstraZeneca
Advanced recurrent and metastatic cervical cancer., Cervical cancer which has come back or spread around the body., Diseases [C] - Cancer [C04]
 
 
2017-001755-31: Study to Compare a Treatment with Trabectedin and Olaparib to Physician’s Choice in Subjects with Previously Treated Solid Tumors Having a Special lack of Cellular Repair Mechanism Studie zu einer Behandlung mit Trabectedin und Olaparib im Vergleich zu Standardbehandlung nach ärztlichem Ermessen bei Patienten mit soliden Tumoren, die eine gestörte Zellreparatur haben.

Not yet recruiting
2
108
Europe
Trabectedin, Olaparib, ET-743, Powder for concentrate for solution for infusion, Film-coated tablet, Yondelis
Ruprecht-Karls-Universität Heidelberg, Medical Faculty, DKFZ Heidelberg, AstraZeneca GmbH, Pharma Mar S.A.
Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies Patienten mit lokal fortgeschrittenen bzw. metastasierten soliden Organtumoren bei molekulargenetisch nachgewiesenen Störungen im DNA-Reparaturweg, Previously Treated Advanced Tumors Fortgeschrittene Krebserkrankung, die bereits behandelt wurde, Diseases [C] - Cancer [C04]
 
 
2018-000230-35: combination of trabectedin and olaparib in ovarian cancer, fallopian tubes and primary of peritoneum already resistant to standard platinum drugs studio di trabectedina e olaparib nei tumori dell'ovaio delle tube di falloppio e dei primitivi del peritoneo in stadio avanzato in cui i trattamenti standard a base di platino non hanno più effetto.

Ongoing
2
66
Europe
yondelis, olaparib, [ET-743], [AZD-2281], Powder for solution for injection, Tablet, YONDELIS - 1 MG POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 1 FLACONCINO
FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCCS, AstraZeneca
platinum-resistant ovarian carcinoma or Fallopian tubes or primary of peritoneum Carcinoma Ovarico, delle tube di Falloppio e dei primitivi del peritoneo platino-resistente, ovarian cancer, fallopian tubes cancer or primary of peritoneum no longer sensitive to standard platinum drugs tumore delle ovaie, delle tube e dei primtivi del peritoneo non più trattabile con i trattamenti standard a base di platino, Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13]
 
 
2016-004384-39: A clinical trial that examines whether the treatment with the medication olaparib in combination with the chemotherapy carboplatin is more effective than treatment with a standard chemotherapy (anthracycline/ taxane-based) against a specific type of breast cancer (triple-negative) with a biologic characteristic (homologous recombination deficiency)

Ongoing
2
90
Europe
Olaparib, Carboplatin, Docetaxel, Doxorubicin, Cyclophosphamide, AZD2281, Film-coated tablet, Solution for infusion, Concentrate for solution for infusion, Powder for solution for injection, Lynparza
Austrian Breast & Colorectal Cancer Study Group (ABCSG), AstraZeneca Österreich GmbH
Early invasive triple negative breast cancer with positive HRD status (acc. to Myriad mychoice© test), Early invasive triple negative breast cancer with positive HRD status, Diseases [C] - Cancer [C04]
 
 
SAFIR02_Lung, NCT02117167 / 2013-001653-27: - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients

Completed
2
999
Europe
AZD2014, AZD4547, AZD5363, AZD8931, Selumetinib, ARRY-142866, Vandetanib, CAPRELSA, Standard maintenance for squamous NSCLC, Pemetrexed, ALIMTA, Durvalumab, savolitinib, Olaparib, LYNPARZA
UNICANCER, Intergroupe Francophone de Cancerologie Thoracique, Fondation ARC, AstraZeneca
Non-small Cell Lung Cancer Metastatic
12/18
12/23
2018-001660-29: FAB: Functional Analysis of BRCAness

Not yet recruiting
2
55
Europe
Olaparib, AZD2281, Film-coated tablet, Olaparib
Leiden University Medical Center, Astra Zeneca, KWF
Recurrent epithelial ovarian cancer Recifief epitheliaal ovarium carcinoom, recurrent ovarian cancer recidief eierstok kanker, Diseases [C] - Cancer [C04]
 
 
2018-001213-32: Effectiveness of olaparib plus trastuzumab in advanced breast cancer patients Eficacia de olaparib en combinación con trastuzumab en pacientes con cáncer de mama avanzado

Not yet recruiting
2
33
Europe
Tablet, Powder for concentrate for solution for infusion, LYNPARZA, Herceptin
Medica Scientia Innovation Research (MedSIR), AstraZeneca Farmacéutica Spain, S.A.
HER2-positive BRCAmutated or Homologous Recombination Deficiency (HRD) advancedbreast cancer Cáncer de mama avanzado HER2-positivo, y con mutación en BRCA o Deficiencia en la Recombinación Homóloga (DRH), Advanced breast cancer Cáncer de mama avanzado, Diseases [C] - Cancer [C04]
 
 
2018-002687-65: nd nd

Not yet recruiting
2
35
Europe
Olaparib, [L01XX46], Tablet
FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE, Astrazeneca
ADVANCED OVARIAN CANCER CARCINOMA OVARICO IN FASE AVANZATA, ADVANCED OVARIAN CANCER CARCINOMA OVARICO IN FASE AVANZATA, Diseases [C] - Cancer [C04]
 
 
2018-002077-21: PHOENIX: A trial to look for markers in the tumour cells and blood which signal that trial drugs are working in a patient with tripe negative breast cancer, for whom upfront chemotherapy has not provided the maximum expected benefit

Not yet recruiting
2
81
Europe
AZD6738 Film-Coated Tablet, Olaparib (Lynparza), Durvalumab, AZD6738, AZD2281, MEDI4736, Film-coated tablet, Tablet, Concentrate for solution for infusion, Olaparib (Lynparza)
The Institute of Cancer Research, AstraZeneca UK Ltd, Cancer Research UK
Triple Negative Breast Cancer, Triple Negative Breast Cancer, Diseases [C] - Cancer [C04]
 
 
2016-002573-35: A study, performed in several centers, to examine the treatment of Olaparib at the time of disease progression in ovarian, peritoneal or fallopian tube cancer before an operation.

Not yet recruiting
2
71
Europe
Lynparza, Carboplatin, Cisplatin, N/A, Tablet, Concentrate for solution for infusion, Lynparza, Carboplatin, Cisplatin
University Health Network, Toronto, AbbVie, AstraZeneca
Platinum Sensitive Recurrent High Grade Serous Ovarian/Primary Peritoneal or Fallopian tube Cancer, Ovarian cancer, Diseases [C] - Cancer [C04]
 
 
2018-003779-36: ATr inhibitor in combination with olaparib in gynaecological cancers with ARId1A loss or no loss.

Not yet recruiting
2
116
Europe
AZD6738, Olaparib (Lynparza), AZD6738, Olaparib (AZD2281), Film-coated tablet, Olaparib (Lynparza)
The Institute of Cancer Research, AstraZeneca UK Limited, Lady Garden Foundation
Relapsed ovarian and endometrial clear cell carcinoma or relapsed other gynaecological cancers (endometriod (ovarian and endometrial), carcinosarcoma (ovarian and endometrial), cerviacal carcinoma (squamous and adenocarcinoma), Relapsed gynaecological cancers of rare subtypes, including clear cell (ovarian/uterus) and carcinosarcoma, cervical and endometrioid type., Diseases [C] - Cancer [C04]
 
 
2019-001316-38: A clinical trial on an individualized treatment strategy for patients with metastatic non-clear cell kidney cancer Et lægemiddelforsøg af en individualiseret behandlingsstrategi til patienter med undertypen non-clear celle nyrekræft, som har spredt sig

Not yet recruiting
2
30
Europe
Capsule, hard, Film-coated tablet, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Tafinlar, Tarceva, Keytruda, Mekinist, Alecensa, Lynparza, Kadcyla, Cabometyx, Xalkori, Ibrance, Tagrisso, Glivec, Sutent, Opdivo
Department of Oncology, Herlev University Hospital, Region Hovedstaden, Roche Denmark
Patients with metastatic non-clear cell or 100% sarcomatoid renal cell carcinoma referred for first line treatment at the Department of Oncology, Herlev University Hospital Patienter med metastatisk non-clear cell eller 100% sarkomatoid nyrekræft, som henvises med henblik på første linje behandling på onkologisk afdeling, Herlev Hospital, Patients with metastatic kidney cancer with the subtype non-clear cell or 100% sarcomatoid referred for first line treatment at the Department of Oncology, Herlev University Hospital Patienter med undertypen non-clear cell eller 100% sarkomatoid nyrekræft, som har spredt sig og henvises for at påbegynde den første medicinske kræftbehandling på onkologisk afdeling, Herlev Hospital, Diseases [C] - Cancer [C04]
 
 
2018-003056-21: Window-of-opportunity clinical trials platform for evaluation of novel treatment strategies in renal cell cancer.

Not yet recruiting
2
76
Europe
Olaparib, Cediranib, Durvalumab, Film-coated tablet, Concentrate for solution for injection/infusion
Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge, AstraZeneca, CRUK Cambridge Centre
Surgically resectable renal cell cancer (Stage M0/M1), Surgically resectable renal cell cancer (Stage M0/M1), Diseases [C] - Cancer [C04]
 
 
2019-004366-18: Phase II study to evaluate MAintenance therapy with olaparib or selumetinib plus durvalumab according to BRCAness and KRAS somatic status Personalized in metastatic Pancreatic Adenocarcinoma patients

Not yet recruiting
2
307
Europe
durvalumab, olaparib 100mg tablet, OLAPARIB 150mg tablet, selumetinib, MEDI4736, AZD2281, AZD6244 blue 25 mg capsule, Concentrate for solution for infusion, Film-coated tablet, Capsule, hard, Lynparza 100 mg film-coated Tablet, Lynparza 150 mg film-coated Tablet
GERCOR, Astra Zeneca
Metastatic Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Diseases [C] - Cancer [C04]
 
 
PETREMAC, NCT02624973: PErsonalized TREatment of High-risk MAmmary Cancer - the Trial

Active, not recruiting
2
200
Europe
Neoadjuvant tamoxifen + goserelin (premenopausal women), Neoadjuvant letrozole (postmenopausal women), Neoadjuvant endocrine therapy + palbociclib (if lack of response to endocrine therapy alone), Neoadjuvant docetaxel + cyclophosphamide, Neoadjuvant docetaxel, Neoadjuvant docetaxel + trastuzumab + pertuzumab, Neoadjuvant docetaxel + cyclophosphamide + trastuzumab + pertuzumab, Neoadjuvant olaparib, Neoadjuvant cyclophosphamide (after 10 weeks of olaparib alone), Breast conserving surgery or mastectomy + SNB/axillary dissection, Postoperative radiotherapy breast/chest wall + regional lymph nodes, Adjuvant trastuzumab, Adjuvant letrozole (postmenopausal women), Adjuvant tamoxifen + goserelin (premenopausal women), Adjuvant palbociclib (if palbociclib given neoadjuvant), Adjuvant Epirubicin+ Cyclophosphamide
Haukeland University Hospital, Helse Vest, Pfizer, AstraZeneca
Breast Cancer
06/20
06/30
BALTIC, NCT02937818 / 2016-001202-42: A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

Checkmark Results in combination with tremelimumab for refractory/resistant ES-SCLC from BALTIC trial
Mar 2022 - Mar 2022: Results in combination with tremelimumab for refractory/resistant ES-SCLC from BALTIC trial
Completed
2
72
Europe, RoW
Durvalumab and Tremelimumab, AZD1775 and carboplatin (CBPT), AZD6738 and olaparib
AstraZeneca
Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma
06/20
11/23
BAYOU, NCT03459846 / 2017-004556-27: A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer

Checkmark From BAYOU trial in combination with Imfinzi for urothelial cancer at ASCO-GU 2022
Feb 2022 - Feb 2022: From BAYOU trial in combination with Imfinzi for urothelial cancer at ASCO-GU 2022
Active, not recruiting
2
154
Europe, Canada, US, RoW
Durvalumab, Olaparib, Placebo
AstraZeneca
Urinary Bladder Neoplasms
10/20
12/24
VIOLETTE, NCT03330847 / 2017-002361-22: To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

Active, not recruiting
2
273
Europe, Canada, US, RoW
Olaparib Continuous (28-Day cycle) 300 mg BD., Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle)., Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).
AstraZeneca
Metastatic Triple Negative Breast Cancer
11/20
09/24
2018-002281-39: Bevacizumab, Olaparib and Durvalumab combination in patients with advanced epithelial ovarian cancer in relapse. Association de bevacizumab, d'Olaparib et de Durvalumab chez des patientes d'un cancer de l'ovaire épithélial avancé en rechute

Not yet recruiting
2
63
Europe
olaparib, Durvalumab, Biosimilar bevacizumab, AZD2281, MEDI4736, FKB238, Tablet, Concentrate for solution for infusion, Olaparib
ARCAGY-GINCO, Astrazeneca
Patients with high grade serous or high grade endometrioid or other high grade epithelial non mucinous ovarian tumor, with at least one previous line of platinum-taxane chemotherapy, and present with platinum resistant disease (PRR) or platinum-sensitive relapse (PSR), whatever the line of chemotherapy given at relapse. Patientes présentant une tumeur ovarienne séreuse ou endometrioïde de haut grade ou autre tumeur épithéliale non mucineuse de haut grade, ayant reçu au moins une ligne de traitement par chimiothérapie par platine-taxane et présentant une rechute soit résistante au platine (RPR), soit sensible au platine (RPS), quelle que soit la ligne de chimiothérapie donnée au moment de la rechute., Patients with advanced epithelial ovarian cancer in relapse Ptientes atteintes d'un cancer de l'ovaire épithélial avancé en rechute, Diseases [C] - Cancer [C04]
 
 
ORION, NCT03775486 / 2018-003460-30: Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer

Hourglass Jul 2021 - Dec 2021 : From ORION trial in combination with Imfinzi for stage IV NSCLC
Hourglass Jan 2020 - Dec 2021 : From ORION trial for NSCLC
Active, not recruiting
2
401
Europe, Japan, US, RoW
Durvalumab, MEDI4736 (Durvalumab), Placebo for Olaparib, Placebo, Olaparib, AZD2281 (Olaparib), Nab-paclitaxel+carboplatin, Gemcitabine+carboplatin, Pemetrexed+carboplatin, Gemcitabine+cisplatin, Pemetrexed+cisplatin
AstraZeneca
Non-small Cell Lung Cancer NSCLC
01/21
09/24
2018-003832-57: Study assessing the efficacy and safety of durvalumab plus olaparib plus fulvestrant in selected metastatic or locally advanced ER-positive, HER2-negative breast cancer patients.

Not yet recruiting
2
166
Europe
Durvalumab, Olaparib, Fulvestrant, Goserelin, MEDI4736, Solution for infusion, Tablet, Solution for injection, Implant in pre-filled syringe, Faslodex, ZOLADEX
UNICANCER, Laboratories AstraZeneca
ER-positive and HER2-negative metastatic or locally advanced breast cancer with either a germline or somatic BRCA mutation, or a deleterious alteration of other genes involved in homologous recombination repair (HRR) or in MSI status., ER-positive and HER2-negative metastatic or locally advanced breast cancer, Diseases [C] - Cancer [C04]
 
 
NCT03516812: Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer

Completed
2
36
US
Laboratory Biomarker Analysis, Olaparib, AZD2281, KU-0059436, Lynparza, PARP Inhibitor AZD2281, Quality-of-Life Assessment, Quality of Life Assessment, Survey Administration, Testosterone Enanthate, Andro LA, Androtardyl, Delatestryl, Everone, Primosteston, Testate, Testinon, Testo-Enant, Testosterone Cypionate, Depo-Testosterone, TC, TCPP, Testosterone cyclopentylpropionate, Testosterone cyclopentanepropionate, Testosterone 17β-cyclopentylpropionate
University of Washington, National Cancer Institute (NCI), AstraZeneca
Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma
03/21
04/24
OCTOVA, NCT03117933 / 2016-000559-28: Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Completed
2
139
Europe
Olaparib, Cediranib, Paclitaxel
University of Oxford, AstraZeneca
Ovarian Cancer
03/21
12/23
2018-004207-39: Mirvetuximab Soravtansine in patients with high expression of folate receptor alpha in their tumor and recurrent ovarian cancer

Not yet recruiting
2
136
Europe
Mirvetuximab Soravtansine, Powder and solvent for concentrate for solution for infusion, Solution for infusion, Capsule, hard, Film-coated tablet, , Caelyx, Carboplatin Kabi, Paclitaxel-GRY®, Gemedac®, Zejula, Lynparza, Rubraca
AGO Research GmbH, ImmunoGen, Inc.
This trial evaluates the efficacy and safety of Mirvetuximab soravtansine (IMGN853) plus Carboplatin chemotherapy in FRα high patients with recurrent ovarian cancer who are eligible for platinum-based chemotherapy., Safety and efficacy for carboplatin with Mirvetuximab soravtansine (IMGN853) compared to carboplatin combination chemotherapy, Diseases [C] - Cancer [C04]
 
 
NCT02822157 / 2015-005838-22: Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer

Active, not recruiting
2
160
Europe
Olaparib, Lynparza, carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly
Universitaire Ziekenhuizen Leuven, AstraZeneca
Ovarian Epithelial Cancer
07/21
07/23
DOMEC, NCT03951415 / 2018-004575-12: Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer

Active, not recruiting
2
55
Europe
PARP inhibitor and Anti-PD-L1, olaparib, durvalumab, PARP inhibitor, Anti-PD-L1 Monoclonal Antibody
Leiden University Medical Center, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Erasmus Medical Center, Maastricht University Medical Center, The Netherlands Cancer Institute, Radboud University Medical Center, University Medical Center Groningen, UMC Utrecht, AstraZeneca
Endometrial Neoplasms, Uterine Neoplasms, Endometrium Cancer
08/21
08/21
2020-004738-39: DOVACC.A study investigating the effect of the medication: olaparib, durvalumb and UV1 as maintenance therapy for patients with Recurrent Ovarian Cancer.

Ongoing
2
184
Europe
UV1, Imfinzi (Durvalumab), LEUKINE, Powder for solution for injection, Tablet, Infusion, Lynparza, Imfinzi, Leukine
Nordic Society of Gynaecological Oncology - Clinical Trial Unit, Ultimovacs, AstraZeneca
Ovarian cancer, Ovarian cancer, Diseases [C] - Cancer [C04]
 
 
2020-001940-25: This is a trial for patients with diagnosed advanced HER2-negative breast cancer and amutation in the genes BRCA1/2, ATM, BARD1, CHEK2, FANCC, PALB2,RAD51C, RAD51D, SLX4, XRCC2 or tumor tissue (homologousrecombination deficiency). The patients will be treated with a combinationof pembrolizumab and olaparib. Diese Studie richtet sich an Patienten mit fortgeschrittenem HER2-negativem Brustkrebsund einer Mutation in den Genen BRCA1/2, ATM, BARD1, CHEK2, FANCC,PALB2, RAD51C, RAD51D, SLX4, XRCC2 oder im Tumorgewebe (homologeRekombinationsdefizienz). Die Patienten werden mit einer Kombinationvon Pembrolizumab und Olaparib behandelt.

Not yet recruiting
2
89
Europe
Olaparib, MK-7339, Concentrate for solution for infusion, Film-coated tablet, KEYTRUDA
Institut für Frauengesundheit GmbH, Merck Sharp & Dohme LLC
patients with unresectable or metastatic HER2 negative breast cancer and a deleterious germlinemutation in BRCA 1/2, ATM, BARD1, CHEK2, FANCC, PALB2, RAD51C, RAD51D, SLX4, XRCC2 or ahomologous recombination deficiency Patienten mit nicht resezierbarem oder metatstasiertem Brustkrebs und einer zum Funktionsverlustführenden Keimbahnmutation in BRCA 1/2, ATM, BARD1, CHEK2, FANCC, PALB2, RAD51C, RAD51D, SLX4, XRCC2 oder einer defekten homologen Rekombination, advanced HER2-negative breast cancer and alterations inparticular genes or tissue (RCA 1/2, ATM, BARD1, CHEK2, FANCC, PALB2,RAD51C, RAD51D, SLX4, XRCC2 or a homologous recombination deficiency) fortgeschrittener HER2-negativer Brustkrebs und Veränderung in speziellen Genen / Gewebe (BRCA 1/2, ATM, BARD1, CHEK2,FANCC, PALB2, RAD51C, RAD51D, SLX4, XRCC2, defekte homologe Rekombination), Diseases [C] - Cancer [C04]
 
 
NCT02953457: Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

Active, not recruiting
2
40
US
Durvalumab, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Laboratory Biomarker Analysis, Olaparib, AZD2281, KU-0059436, Lynparza, PARP Inhibitor AZD2281, Tremelimumab, Anti-CTLA4 Human Monoclonal Antibody CP-675,206, CP-675, CP-675,206, CP-675206, Ticilimumab
Roswell Park Cancer Institute, AstraZeneca
BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
09/21
10/24
2020-005101-12: A clinical trial to test the feasibility of a treatment with Olaparib (cohort A) or Olaparib in combination with Durvalumab (cohort B) given to patients with ovarian cancer during the time slot between diagnosis and primary debulking surgery.

Not yet recruiting
2
60
Europe
Olaparib, Durvalumab, AZD2281, KU-0059436, MEDI4736, Tablet, Concentrate for concentrate for solution for infusion, Lynparza, Imfinzi
AGO Research GmbH, AstraZeneca GmbH
Patients with presumed and previously untreated advanced stage ovarian cancer planned to undergo laparoscopy for histologic diagnosis and treatment planning., Patients with presumed and previously untreated advanced stage ovarian cancer planned to undergo laparoscopy for histologic diagnosis and treatment planning, Diseases [C] - Cancer [C04]
 
 
2021-003767-10: Pembrolizumab and Olaparib in homologous-recombination deficient (HRD) advanced colorectal cancer (CRC). Pembrolizumab y Olaparib en cáncer colorrectal avanzado (CCR) con reparación de recombinación homóloga deficiente (HRD).

Not yet recruiting
2
40
Europe
Pembrolizumab, Olaparib, MK-3475, MK-7339, Solution for infusion, Film-coated tablet, KEYTRUDA (pembrolizumab, MK-3475)
Grupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD), Merck Sharp & Dohme Corp. (MSD)
Homologous-recombination repair deficient (HRD) advanced colorectal cancer (CRC) Cáncer colorrectal avanzado (CCR) con reparación de recombinación homóloga deficiente (HRD)., Advanced colorectal cancer (CRC) with HRD Cáncer colorrectal avanzado (CCR) con HRD, Diseases [C] - Cancer [C04]
 
 
AMBITION, NCT03699449: An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer

Recruiting
2
104
RoW
olaparib+cediranib combination therapy, durvalumab + olaparib combination therapy, durvalumab + chemotherapy treatment, durvalumab + tremelimumab + chemotherapy treatment, durvalumab + tremelimumab + paclitaxel treatment, durvalumab +chemotherapy treatment
Yonsei University, AstraZeneca, Samsung Genomic Institute, Seoul National University Hospital, Samsung Medical Center, Korean Gynecologic Oncology Group
Platinum-resistant Recurrent Ovarian Cancer
09/22
09/22
2020-004834-39: Treatment of extensive small cell lung cancer (ES-SCLC) with chemo-immunotherapy followed by a maintenance phase with Pembrolizumab and Olaparib. Trattamento del carcinoma polmonare a piccole cellule in stadio esteso (ES-SCLC) con chemio-immunoterapia seguita da una fase di mantenimento con Pembrolizumab e Olaparib.

Not yet recruiting
2
60
Europe
Olaparib, Pembrolizumab, [MK-7339], [MK-3475], Film-coated tablet, Solution for injection/infusion, Keytruda (pembrolizumab, MK-3475)
ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS, Merck Sharp & Dohme (MSD)
Extensive-Stage Small-Cell Lung Cancer (ES SCLC) Carcinoma polmonare a piccole cellule in stadio esteso (ES SCLC), Extensive-Stage Small-Cell Lung Cancer (ES SCLC) Carcinoma polmonare a piccole cellule in stadio esteso (ES SCLC), Diseases [C] - Cancer [C04]
 
 
SAFIR02_Breast, NCT02299999: - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

Active, not recruiting
2
1460
Europe
AZD2014, AZD4547, AZD5363, AZD8931, Selumetinib, ARRY-142866, Vandetanib, CAPRELSA, Bicalutamide, Casodex, Olaparib, Lynparza, Anthracyclines, Doxorubicin, Epirubicin, liposomal doxorubicin, Taxanes, paclitaxel, docetaxel, cyclophosphamide, Novatrex, Imeth, DNA intercalators, capecitabine, 5-FU, gemcitabine, Methotrexate, vinca alkaloids, vinorelbine, vinblastine, vincristine, Platinum based chemotherapies, Platinum, carboplatin, cisplatin, Bevacizumab, Avastin, Mitomycin C, Ametycine, Eribulin, Halaven, MEDI4736
UNICANCER, Fondation ARC, AstraZeneca
Metastatic Breast Cancer
12/22
12/24
KEYLYNK-009, NCT04191135 / 2019-001892-35: Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/)

Active, not recruiting
2
462
Europe, Canada, Japan, US, RoW
Pembrolizumab, KEYTRUDA®, MK-3475, Olaparib, LYNPARZA®, MK-7339, AZD2281, KU-0059436, Carboplatin, PARAPLATIN®, Gemcitabine, GEMZAR®
Merck Sharp & Dohme LLC
Triple Negative Breast Neoplasms
12/22
11/25
NCT04076579: Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma

Active, not recruiting
2
29
US
Olaparib, Trabectedin
University of Michigan Rogel Cancer Center, Janssen Scientific Affairs, LLC, AstraZeneca
Sarcoma, Sarcoma Metastatic
01/23
01/25
COPELIA, NCT03570437: Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel?

Active, not recruiting
2
124
Europe
Paclitaxel, L01CD01, Cediranib, AZD2171, 288383-20-0, Olaparib, AZD2281, Lynparza, L01XX46
University of Manchester, AstraZeneca, Cardiff University
Carcinosarcoma, Endometrial Neoplasms
01/23
06/23
GUIDE2REPAIR, NCT04169841: Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment

Active, not recruiting
2
270
Europe
olaparib, durvalumab, tremelimumab
Centre Georges Francois Leclerc, AstraZeneca
Immunotherapy
08/27
08/27
CUPISCO, NCT03498521 / 2017-003040-20: A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site

Active, not recruiting
2
528
Europe, Japan, RoW
Alectinib, Vismodegib, Ipatasertib, Olaparib, Erlotinib, Bevacizumab, Vemurafenib, Cobimetinib, Trastuzumab Subcutaneous (SC), Pertuzumab, Atezolizumab, Carboplatin, Paclitaxel, Cisplatin, Gemcitabine, Entrectinib, Ivosidenib, Pemigatinib
Hoffmann-La Roche, Foundation Medicine, Inc.
Cancer of Unknown Primary Site
02/23
06/24
NCT04669002 / 2020-003083-98: EP0057 in Combination With Olaparib in Advanced Ovarian Cancer

Completed
2
34
Europe, US
EP0057, Olaparib tablets, Lynparza
Ellipses Pharma
Ovarian Cancer
02/23
05/23
PHOENIX, NCT03740893: DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer

Recruiting
2
81
Europe
AZD6738, Olaparib, Durvalumab
Institute of Cancer Research, United Kingdom, AstraZeneca
Breast Neoplasm
03/23
12/25
ATARI, NCT04065269: ATr Inhibitor in Combination With Olaparib in Gynaecological Cancers With ARId1A Loss or no Loss

Recruiting
2
40
Europe
AZD6738, Olaparib
Institute of Cancer Research, United Kingdom, Cancer Research UK, AstraZeneca
Gynaecological Cancers
03/23
03/23
NCT03047135: Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis

Active, not recruiting
2
50
US
Olaparib
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, AstraZeneca
Prostate
05/23
02/25
2021-004455-17: Non‐Randomized, Open‐Label, Prospective Phase II Trial to Better Characterize the Status of HRD leading to a Benefit from Olaparib in Combination with Bevacizumab in Patients with Advanced FIGO Stage III‐IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer After Standard First‐Line Treatment Ensayo clínico no aleatorizado, abierto, prospectivo, de fase II para mejorar la caracterización del estado de la HRD y optimizar el beneficio clínico de olaparib en combinación con bevacizumab, en pacientes con cáncer de ovario seroso de alto grado o endometrioide, de trompa de Falopio o peritoneal avanzado (FIGO III-IV), tras tratamiento estándar de primera línea.

Not yet recruiting
2
150
Europe
Film-coated tablet, Concentrate for solution for infusion, Lynparza 100 mg, Lynparza 150 mg, Avastin
VHIO Vall d’Hebron Institute of Oncology, Astra Zeneca
Patients with Advanced FIGO Stage III‐IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer After Standard First‐Line Treatment Pacientes con cáncer de ovario seroso de alto grado o endometrioide, de trompa de Falopio o peritoneal avanzado (FIGO III-IV), tras tratamiento estándar de primera línea, Patients Ovarian, Fallopian Tube, or Peritoneal Cancer Pacientes con cáncer de ovario, de trompa de Falopio o peritoneal, Diseases [C] - Cancer [C04]
 
 
NCT03448718: Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations

Completed
2
19
US
Olaparib, Lynparza
Matthew Galsky, Icahn School of Medicine at Mount Sinai, AstraZeneca
Metastatic Urothelial Cancer
07/21
10/21
SUKSES-B2, NCT04939662: Olaparib and Bevacizumab in Relapsed Small Cell Lung Cancer Subjects

Completed
2
25
RoW
Olaparib+Bevacizumab to SCLC patients, Drug Combination Intervention
Se-Hoon Lee, AstraZeneca, Roche Pharma AG
Lung Cancer
10/23
10/23
2022-003594-33: Olaparib and durvalumab before surgery as treatment for patients with a BRCA-associated triple negative subtype of breast cancer (NOBLE)

Ongoing
2
152
Europe
Olaparib, Durvalumab, Film-coated tablet, Concentrate for solution for infusion, Lynparza, Imfinzi
European Organisation for Research and Treatment of Cancer (EORTC), EORTC, AstraZeneca UK Limited
Triple negative breast cancer, Cancer of breast, Diseases [C] - Cancer [C04]
 
 
OLAPem, NCT04417192: Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian Cancer

Completed
2
30
Japan
Olaparib, Pembrolizumab
National Cancer Center Hospital East, Merck Sharp & Dohme LLC
Ovarian Cancer
06/23
06/23
NCT05005728: XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Recruiting
2
85
US
vudalimab + carboplatin + cabazitaxel, vudalimab + olaparib, vudalimab monotherapy, vudalimab + docetaxel, vudalimab + cabazitaxel or docetaxel
Xencor, Inc.
Metastatic Castration-Resistant Prostate Cancer
03/25
09/25
D19-02, NCT04348045: Personalized Maintenance Therapy for m-PDAC Using Olaparib or Selumetinib + Durvalumab, Based on BRCAness and KRAS Status.

Active, not recruiting
2
307
Europe
Arm A - Olaparib, AZD-2281, ARM B - durvalumab plus selumetinib, MEDI-4736 plus AZD-6244, ARM C FOLFIRI, folinic acid, fluorouracil, and irinotecan
GERCOR - Multidisciplinary Oncology Cooperative Group, AstraZeneca
Metastatic Pancreatic Adenocarcinoma
07/23
12/24
NCT03025035: Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer

Recruiting
2
20
US
Pembrolizumab, Keytruda, MK-3475, Olaparib, Lynparza
Monica Mita, Merck Sharp & Dohme LLC
Breast Cancer
08/26
08/26
NCT-PMO-1603, NCT03127215: Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid Tumors

Completed
2
102
Europe
Olaparib, Physician's choice, Trabectedin
National Center for Tumor Diseases, Heidelberg, AstraZeneca, PharmaMar, German Cancer Research Center
Cancers With DNA Repair-Deficiency
12/23
12/23
DAPPER, NCT03851614: Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors

Active, not recruiting
2
90
Canada
Durvalumab, Imfinzi, Olaparib, Lynparza, AZD2281, Cediranib, AZD2171
University Health Network, Toronto, AstraZeneca
Mismatch Repair Proficient Colorectal Cancer, Pancreatic Adenocarcinoma, Leiomyosarcoma
01/25
01/25
NCT05174832: Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients

Recruiting
2
136
RoW
Cisplatin, Nab-paclitaxel, Pembrolizumab, keytruda, Olaparib, LYNPARZA
Fudan University, Merck Sharp & Dohme LLC
Triple Negative Breast Cancer
12/23
03/25
NePtune, NCT05498272: Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With BRCA1/2 Gene Alterations

Recruiting
2
32
US
Olaparib, Lynparza, LHRH agonist, Goserelin, Triptorelin, Leuprolide
Rana McKay, MD, AstraZeneca, University of California, San Diego
Prostate Cancer, BRCA1 Mutation, BRCA2 Mutation, Prostatic Adenocarcinoma, High-Risk Cancer
12/25
12/26
TBCRC 048, NCT03344965: Olaparib In Metastatic Breast Cancer

Active, not recruiting
2
114
US
Olaparib, AZD2281, KU-0059436
Beth Israel Deaconess Medical Center, Johns Hopkins University, AstraZeneca, Dana-Farber Cancer Institute
Metastatic Breast Cancer, Invasive Breast Cancer, Somatic Mutation Breast Cancer (BRCA1), Somatic Mutation Breast Cancer (BRCA2), CHEK2 Gene Mutation, ATM Gene Mutation, PALB2 Gene Mutation, RAD51 Gene Mutation, BRIP1 Gene Mutation, NBN Gene Mutation
07/24
12/24
NCI-2015-01097, NCT02498613: A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

Active, not recruiting
2
122
Canada, US
18F-Fluoromisonidazole, 18F-MISO, 18F-Misonidazole, FLUOROMISONIDAZOLE F-18, FMISO, Cediranib Maleate, AZD2171, AZD2171 Maleate, Recentin, Laboratory Biomarker Analysis, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
National Cancer Institute (NCI), AstraZeneca
Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Metastatic Triple-Negative Breast Carcinoma, Pancreatic Ductal Adenocarcinoma, Stage III Breast Cancer AJCC v7, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage III Lung Small Cell Carcinoma AJCC v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Small Cell Carcinoma AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Small Cell Carcinoma AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Small Cell Carcinoma AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma, Unresectable Lung Small Cell Carcinoma, Unresectable Pancreatic Adenocarcinoma, Unresectable Pancreatic Carcinoma, Unresectable Triple-Negative Breast Carcinoma
06/22
04/25
 

Download Options